Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems.

IF 8.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-08-11 DOI:10.1080/10717544.2025.2544689
Zhihao Lin, Ziheng Zhao, Xianrui Lin, Zhenlin Yang, Lin Wang, Rui Xi, Dingpei Long
{"title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems.","authors":"Zhihao Lin, Ziheng Zhao, Xianrui Lin, Zhenlin Yang, Lin Wang, Rui Xi, Dingpei Long","doi":"10.1080/10717544.2025.2544689","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) comprises chronic autoimmune disorders with significant morbidity, highlighting the need for advanced, noninvasive, targeted therapies. Protein-based nanoparticle drug delivery systems (PNP-DDSs) have emerged as promising platforms to overcome limitations of conventional IBD therapies by improving drug stability and bioavailability while enabling colon-specific delivery. This review systematically classifies PNP-DDSs derived from natural proteins (albumin, gelatin, silk fibroin, and plant-derived proteins) and discusses their design principles along with strategies for intestinal targeting, including particle size and surface charge modulation, stimuli-responsive release (triggered by pH, reactive oxygen species, or enzymes), and active targeting. It highlights recent preclinical advances with oral PNP-DDSs delivering curcumin, resveratrol, 5-aminosalicylic acid, quercetin, and other anti-inflammatory agents, which demonstrate the therapeutic potential of these nanoplatforms in IBD models. Despite promising preclinical outcomes, clinical translation of PNP-DDSs remains challenging due to patient heterogeneity, manufacturing scale-up difficulties, and safety concerns. Future progress will require interdisciplinary innovation and optimization of multi‑stimuli-responsive designs for precise and safe clinical application of PNP-DDSs in IBD management.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2544689"},"PeriodicalIF":8.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344685/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2025.2544689","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease (IBD) comprises chronic autoimmune disorders with significant morbidity, highlighting the need for advanced, noninvasive, targeted therapies. Protein-based nanoparticle drug delivery systems (PNP-DDSs) have emerged as promising platforms to overcome limitations of conventional IBD therapies by improving drug stability and bioavailability while enabling colon-specific delivery. This review systematically classifies PNP-DDSs derived from natural proteins (albumin, gelatin, silk fibroin, and plant-derived proteins) and discusses their design principles along with strategies for intestinal targeting, including particle size and surface charge modulation, stimuli-responsive release (triggered by pH, reactive oxygen species, or enzymes), and active targeting. It highlights recent preclinical advances with oral PNP-DDSs delivering curcumin, resveratrol, 5-aminosalicylic acid, quercetin, and other anti-inflammatory agents, which demonstrate the therapeutic potential of these nanoplatforms in IBD models. Despite promising preclinical outcomes, clinical translation of PNP-DDSs remains challenging due to patient heterogeneity, manufacturing scale-up difficulties, and safety concerns. Future progress will require interdisciplinary innovation and optimization of multi‑stimuli-responsive designs for precise and safe clinical application of PNP-DDSs in IBD management.

基于蛋白质的纳米颗粒给药系统口服治疗炎症性肠病的进展。
炎症性肠病(IBD)包括具有显著发病率的慢性自身免疫性疾病,突出了对先进、无创、靶向治疗的需求。基于蛋白质的纳米颗粒给药系统(pnp - dss)已经成为克服传统IBD治疗局限性的有前途的平台,通过提高药物稳定性和生物利用度,同时实现结肠特异性给药。本文系统地对天然蛋白(白蛋白、明胶、丝素蛋白和植物源蛋白)衍生的pnp - dss进行了分类,并讨论了它们的设计原则以及肠道靶向策略,包括粒径和表面电荷调节、刺激响应释放(由pH、活性氧或酶触发)和主动靶向。它强调了口服pnp - dss提供姜黄素、白藜芦醇、5-氨基水杨酸、槲皮素和其他抗炎药物的临床前进展,这些纳米平台在IBD模型中的治疗潜力。尽管有很好的临床前结果,但由于患者异质性、生产规模困难和安全性问题,pnp - dss的临床转化仍然具有挑战性。未来的进展将需要跨学科的创新和多刺激响应设计的优化,以实现pnp - dss在IBD管理中的精确和安全的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Delivery
Drug Delivery 医学-药学
CiteScore
11.80
自引率
5.00%
发文量
250
审稿时长
3.3 months
期刊介绍: Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信